모델 정보

BioMistral-7B

BioMistral · BioMistral-7B

Large Language Models (LLMs) have demonstrated remarkable versatility in recent years, offering potential applications across specialized domains such as healthcare and medicine. Despite the availability of various open-source LLMs tailored for health contexts, adapting general-purpose LLMs to the medical domain presents significant challenges. In this paper, we introduce BioMistral, an open-source LLM tailored for the biomedical domain, utilizing Mistral as its foundation model and further pre-trained on PubMed Central. We conduct a comprehensive evaluation of BioMistral on a benchmark comprising 10 established medical question-answering (QA) tasks in English. We also explore lightweight models obtained through quantization and model merging approaches. Our results demonstrate BioMistral's superior performance compared to existing open-source medical models and its competitive edge against proprietary counterparts. Finally, to address the limited availability of data beyond English and to assess the multilingual generalization of medical LLMs, we automatically translated and evaluated this benchmark into 7 other languages. This marks the first large-scale multilingual evaluation of LLMs in the medical domain. Datasets, multilingual evaluation benchmarks, scripts, and all the models obtained during our experiments are freely released. **Advisory Notice!** Although BioMistral is intended to encapsulate medical knowledge sourced from high-quality evidence, it hasn't been tailored to effectively, safely, or suitably convey this knowledge within professional parameters for action. We advise refraining from utilizing BioMistral in medical contexts unless it undergoes thorough alignment with specific use cases and undergoes further testing, notably including randomized controlled trials in real-world medical environments. BioMistral 7B may possess inherent risks and biases that have not yet been thoroughly assessed. Additionally, the model's performance has not been evaluated in real-world clinical settings. Consequently, we recommend using BioMistral 7B strictly as a research tool and advise against deploying it in production environments for natural language generat

번역 대기 중입니다. 원문을 표시합니다.

텍스트 생성license:apache-2.0
컨텍스트 창미공개
입력 → 출력텍스트 → 텍스트
모델 웨이트미확인
정보 업데이트2026/11/2 19:15:29
OVERVIEW

모델 소개

Large Language Models (LLMs) have demonstrated remarkable versatility in recent years, offering potential applications across specialized domains such as healthcare and medicine. Despite the availability of various open-source LLMs tailored for health contexts, adapting general-purpose LLMs to the medical domain presents significant challenges. In this paper, we introduce BioMistral, an open-source LLM tailored for the biomedical domain, utilizing Mistral as its foundation model and further pre-trained on PubMed Central. We conduct a comprehensive evaluation of BioMistral on a benchmark comprising 10 established medical question-answering (QA) tasks in English. We also explore lightweight models obtained through quantization and model merging approaches. Our results demonstrate BioMistral's superior performance compared to existing open-source medical models and its competitive edge against proprietary counterparts. Finally, to address the limited availability of data beyond English and to assess the multilingual generalization of medical LLMs, we automatically translated and evaluated this benchmark into 7 other languages. This marks the first large-scale multilingual evaluation of LLMs in the medical domain. Datasets, multilingual evaluation benchmarks, scripts, and all the models obtained during our experiments are freely released. **Advisory Notice!** Although BioMistral is intended to encapsulate medical knowledge sourced from high-quality evidence, it hasn't been tailored to effectively, safely, or suitably convey this knowledge within professional parameters for action. We advise refraining from utilizing BioMistral in medical contexts unless it undergoes thorough alignment with specific use cases and undergoes further testing, notably including randomized controlled trials in real-world medical environments. BioMistral 7B may possess inherent risks and biases that have not yet been thoroughly assessed. Additionally, the model's performance has not been evaluated in real-world clinical settings. Consequently, we recommend using BioMistral 7B strictly as a research tool and advise against deploying it in production environments for natural language generat

주요 특징

特点摘要待依据来源补齐,不凭模型名称推断能力。

한계 및 유의 사항

구체적 한계를 판단할 출처가 부족합니다. 실제 성능, 지연, 데이터 정책, 라이선스와 버전 수명을 확인하세요.

PRICING & COST

출처별 요금 및 비용 분석

요금은 채널, 지역, 설정에 따라 다릅니다. 각 채널 요금은 개별 표시되며 제공사의 통일 공식 요금이 아닙니다.

출처 / 채널입력출력과금 단위수집 시간
확인된 요금이 없습니다. 출처를 확인하세요.

월간 기본 토큰 비용 추정

—

추정치에는 캐시 할인, 구간 요금, 멀티모달 추가 요금, 검색, 세금 및 추가 추론 출력이 포함되지 않습니다.

INDEPENDENT BENCHMARKS

공개 평가 및 실행 설정

暂无已采集的可核验公开评分。模型未上榜不代表能力较低。

등록된 전체 순위 보기 →

자주 묻는 질문

오픈 웨이트면 무료 상업 이용이 가능한가요?

반드시 그렇지는 않습니다. 버전별 라이선스, 상업 이용 조건과 정책을 확인하세요. 자체 배포에는 연산 및 유지 비용도 듭니다.

실시간 결제 요금인가요?

수집 시간이 기록된 요금 스냅샷입니다. 최신 버전, 지역, 할인과 과금 방식은 해당 채널에서 확인하세요.

출처 및 추적 기록

许可证:apache-2.0。模型介绍与第三方评测均以原来源的具体版本和方法为准。